Helius Medical Technologies Inc (HSDT)

$0.53

Market is closed - opens 7 PM, 04 Oct 2024

Performance

  • $0.52
    $0.55
    $0.53
    downward going graph

    1.89%

    Downside

    Day's Volatility :6.2%

    Upside

    4.4%

    downward going graph
  • $0.53
    $9.89
    $0.53
    downward going graph

    0.0%

    Downside

    52 Weeks Volatility :94.64%

    Upside

    94.64%

    downward going graph

Returns

PeriodHelius Medical Technologies IncIndex (Russel 2000)
3 Months
-40.36%
0.0%
6 Months
-91.34%
0.0%
1 Year
-94.13%
0.0%
3 Years
-99.92%
-21.1%

Highlights

Market Capitalization
2.7M
Book Value
$1.98
Earnings Per Share (EPS)
-9.7
PEG Ratio
0.0
Wall Street Target Price
4.0
Profit Margin
0.0%
Operating Margin TTM
-1796.7%
Return On Assets TTM
-76.06%
Return On Equity TTM
-161.97%
Revenue TTM
594.0K
Revenue Per Share TTM
0.51
Quarterly Revenue Growth YOY
-28.9%
Gross Profit TTM
324.0K
EBITDA
-11.8M
Diluted Eps TTM
-9.7
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-5.66
EPS Estimate Next Year
-2.38
EPS Estimate Current Quarter
-0.5
EPS Estimate Next Quarter
-0.98

Analyst Recommendation

Buy
    88%Buy
    11%Hold
    0
    0%Sell
Based on 9 Wall street analysts offering stock ratings for Helius Medical Technologies Inc(by analysts ranked 0 to 5 stars)
Based on 9 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
8
8
7
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 654.72%

Current $0.53
Target $4.00

Company Financials

FY18Y/Y Change
Revenue
478.0K
-
Net Income
-28.6M
↑ 2.14%
Net Profit Margin
-6.0K%
-
FY19Y/Y Change
Revenue
1.5M
↑ 212.97%
Net Income
4.3M
↓ 115.16%
Net Profit Margin
290.04%
↑ 6278.12%
FY20Y/Y Change
Revenue
661.0K
↓ 55.82%
Net Income
-13.9M
↓ 421.2%
Net Profit Margin
-2.1K%
↓ 2398.51%
FY21Y/Y Change
Revenue
522.0K
↓ 21.03%
Net Income
-18.1M
↑ 30.03%
Net Profit Margin
-3.5K%
↓ 1363.18%
FY22Y/Y Change
Revenue
787.0K
↑ 50.77%
Net Income
-12.6M
↓ 30.7%
Net Profit Margin
-1.6K%
↑ 1875.97%
FY23Y/Y Change
Revenue
644.0K
↓ 18.17%
Net Income
-8.9M
↓ 29.53%
Net Profit Margin
-1.4K%
↑ 221.46%
Q1 FY23Q/Q Change
Revenue
111.0K
↓ 60.64%
Net Income
-1.1M
↓ 85.02%
Net Profit Margin
-971.17%
↑ 1579.89%
Q2 FY23Q/Q Change
Revenue
256.0K
↑ 130.63%
Net Income
-1.6M
↑ 52.88%
Net Profit Margin
-643.75%
↑ 327.42%
Q3 FY23Q/Q Change
Revenue
143.0K
↓ 44.14%
Net Income
-3.7M
↑ 122.27%
Net Profit Margin
-2.6K%
↓ 1917.79%
Q4 FY23Q/Q Change
Revenue
134.0K
↓ 6.29%
Net Income
-1.0M
↓ 71.47%
Net Profit Margin
-779.85%
↑ 1781.69%
Q1 FY24Q/Q Change
Revenue
135.0K
↑ 0.75%
Net Income
-2.5M
↑ 140.77%
Net Profit Margin
-1.9K%
↓ 1083.85%
Q2 FY24Q/Q Change
Revenue
182.0K
↑ 34.81%
Net Income
-1.6M
↓ 35.93%
Net Profit Margin
-885.71%
↑ 977.99%
FY18Y/Y Change
Total Assets
27.8M
↑ 308.68%
Total Liabilities
18.0M
↑ 25.69%
FY19Y/Y Change
Total Assets
10.3M
↓ 62.82%
Total Liabilities
4.5M
↓ 74.9%
FY20Y/Y Change
Total Assets
6.5M
↓ 36.73%
Total Liabilities
2.7M
↓ 40.69%
FY21Y/Y Change
Total Assets
14.1M
↑ 115.4%
Total Liabilities
2.8M
↑ 6.35%
FY22Y/Y Change
Total Assets
17.3M
↑ 22.59%
Total Liabilities
9.1M
↑ 221.01%
FY23Y/Y Change
Total Assets
7.7M
↓ 55.5%
Total Liabilities
5.3M
↓ 41.53%
Q1 FY23Q/Q Change
Total Assets
13.8M
↓ 20.43%
Total Liabilities
7.7M
↓ 15.85%
Q2 FY23Q/Q Change
Total Assets
10.8M
↓ 21.82%
Total Liabilities
6.2M
↓ 19.6%
Q3 FY23Q/Q Change
Total Assets
8.9M
↓ 17.66%
Total Liabilities
5.8M
↓ 5.63%
Q4 FY23Q/Q Change
Total Assets
7.7M
↓ 13.12%
Total Liabilities
5.3M
↓ 8.42%
Q1 FY24Q/Q Change
Total Assets
5.8M
↓ 25.16%
Total Liabilities
3.8M
↓ 29.41%
Q2 FY24Q/Q Change
Total Assets
8.8M
↑ 53.66%
Total Liabilities
2.5M
↓ 33.52%
FY18Y/Y Change
Operating Cash Flow
-19.6M
↑ 1.53%
Investing Cash Flow
-440.0K
↑ 131.58%
Financing Cash Flow
40.0M
↑ 80.16%
FY19Y/Y Change
Operating Cash Flow
-21.0M
↑ 7.02%
Investing Cash Flow
-769.0K
↑ 74.77%
Financing Cash Flow
1.7M
↓ 95.87%
FY20Y/Y Change
Operating Cash Flow
-11.7M
↓ 44.1%
Investing Cash Flow
-9.0K
↓ 98.83%
Financing Cash Flow
9.6M
↑ 483.06%
FY21Y/Y Change
Operating Cash Flow
-13.4M
↑ 14.06%
Investing Cash Flow
-56.0K
↑ 522.22%
Financing Cash Flow
21.1M
↑ 119.19%
FY22Y/Y Change
Operating Cash Flow
-14.3M
↑ 6.89%
Investing Cash Flow
-11.0K
↓ 80.36%
Financing Cash Flow
17.9M
↓ 15.42%
Q1 FY23Q/Q Change
Operating Cash Flow
-3.2M
↑ 48.86%
Investing Cash Flow
-1000.0
↓ 150.0%
Financing Cash Flow
0.0
↓ 100.0%
Q2 FY23Q/Q Change
Operating Cash Flow
-2.7M
↓ 14.11%
Investing Cash Flow
-1000.0
↑ 0.0%
Financing Cash Flow
0.0
-

Technicals Summary

Sell

Neutral

Buy

Helius Medical Technologies Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Helius Medical Technologies Inc
Helius Medical Technologies Inc
-34.46%
-91.34%
-94.13%
-99.92%
-99.98%
Stryker Corporation
Stryker Corporation
0.46%
2.92%
35.88%
37.71%
69.5%
Boston Scientific Corp.
Boston Scientific Corp.
3.28%
23.0%
62.59%
97.59%
110.82%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
-4.01%
-29.06%
-5.19%
-37.96%
-11.22%
Abbott Laboratories
Abbott Laboratories
-0.57%
2.45%
19.02%
-1.32%
40.63%
Medtronic Plc
Medtronic Plc
1.2%
5.92%
17.62%
-28.0%
-15.8%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Helius Medical Technologies Inc
Helius Medical Technologies Inc
0.14
NA
0.0
-5.66
-1.62
-0.76
NA
1.98
Stryker Corporation
Stryker Corporation
40.27
40.27
2.65
12.0
0.19
0.07
0.01
51.86
Boston Scientific Corp.
Boston Scientific Corp.
68.13
68.13
2.06
2.41
0.09
0.05
NA
13.85
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
25.98
25.98
3.51
2.63
0.22
0.12
NA
12.35
Abbott Laboratories
Abbott Laboratories
35.41
35.41
4.16
4.66
0.14
0.06
0.02
22.6
Medtronic Plc
Medtronic Plc
30.31
30.31
1.67
5.2
0.08
0.04
0.03
37.39
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Helius Medical Technologies Inc
Helius Medical Technologies Inc
Buy
$2.7M
-99.98%
0.14
0.0%
Stryker Corporation
Stryker Corporation
Buy
$137.7B
69.5%
40.27
16.12%
Boston Scientific Corp.
Boston Scientific Corp.
Buy
$123.4B
110.82%
68.13
12.0%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
Buy
$40.1B
-11.22%
25.98
23.74%
Abbott Laboratories
Abbott Laboratories
Buy
$198.4B
40.63%
35.41
13.65%
Medtronic Plc
Medtronic Plc
Buy
$115.5B
-15.8%
30.31
12.06%

Insights on Helius Medical Technologies Inc

  • Increasing Revenue

    Revenue is up for the last 3 quarters, 134.0K → 182.0K (in $), with an average increase of 13.3% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -2.51M → -1.61M (in $), with an average increase of 56.1% per quarter

  • Vs BSX

    In the last 1 year, Boston Scientific Corp. has given 62.6% return, outperforming this stock by 156.7%

  • Vs BSX

    In the last 3 years, Boston Scientific Corp. has given 91.3% return, outperforming this stock by 191.2%

Institutional Holdings

  • Armistice Capital, LLC

    3.64%

  • Susquehanna International Group, LLP

    0.45%

  • Geode Capital Management, LLC

    0.41%

  • Vanguard Group Inc

    0.35%

  • Tower Research Capital LLC

    0.19%

  • UBS Group AG

    0.04%

Company Information

helius medical technologies, inc., a neurotechnology company, focuses on developing, licensing, and acquiring non-invasive technologies for the treatment of symptoms caused by neurological disease or trauma. the company's product is portable neuromodulation stimulator (pons), a medical device in canada for the treatment of chronic balance deficit due to mild-to-moderate traumatic brain injury. its pons device treats neurostimulation of cranial nerves via the tongue to restore lost function. the company is headquartered in newtown, pennsylvania.

Organization
Helius Medical Technologies Inc
Employees
22
CEO
Mr. Dane Carl Andreeff
Industry
Health Technology

Discover More

FAQs